(ATIP) ATI Physical Therapy - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00216W1099
ATIP: Physical, Therapy, Rehabilitation, Sports, Medicine, Wellness, Injury, Prevention
ATI Physical Therapy, Inc. (NYSE: ATIP) is a leading outpatient physical therapy provider specializing in rehabilitation and adjacent healthcare services across the United States. Founded in 1996 and headquartered in Bolingbrook, Illinois, the company operates a network of outpatient clinics under the ATI brand, offering a comprehensive suite of services tailored to address a wide range of injuries and conditions. Its core offerings include physical therapy for spine, shoulder, knee, and neck injuries or pain, as well as work injury rehabilitation, hand therapy, aquatic therapy, and functional capacity evaluations. Additionally, the company provides sports medicine services, including on-site physical therapy, clinical evaluations, and concussion management. ATI also delivers employer-focused solutions such as injury prevention programs, work-related injury assessments, and wellness consultations. The company leverages proprietary electronic medical records (EMR) systems to streamline operations and enhance patient care. Its services are designed to improve functional outcomes and reduce healthcare costs for patients and employers alike.
From a technical perspective, ATIP has shown volatility in recent trading sessions, with an Average True Range (ATR) of 0.19. The stock is currently trading below its 20-day and 50-day Simple Moving Averages (SMA), which are 1.16 and 1.52, respectively. However, it remains significantly below its 200-day SMA of 3.91, indicating a potential long-term downtrend. On the fundamental side, ATI Physical Therapy has a market capitalization of $5.90 million, with a price-to-book (P/B) ratio of 0.45, suggesting undervaluation relative to its book value. The return on equity (RoE) stands at 34.83, indicating efficient profitability from shareholders equity. However, the lack of forward P/E and the extremely low P/S ratio of 0.01 highlight significant challenges in valuation and revenue generation.
Additional Sources for ATIP Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ATIP Stock Overview
Market Cap in USD | 6m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2020-10-02 |
ATIP Stock Ratings
Growth 5y | -87.3% |
Fundamental | 10.4% |
Dividend | 0.0% |
Rel. Strength Industry | -80 |
Analysts | 3/5 |
Fair Price Momentum | 0.59 USD |
Fair Price DCF | - |
ATIP Dividends
No Dividends PaidATIP Growth Ratios
Growth Correlation 3m | -14% |
Growth Correlation 12m | -57.7% |
Growth Correlation 5y | -98.7% |
CAGR 5y | -74.04% |
CAGR/Max DD 5y | -0.74 |
Sharpe Ratio 12m | -0.02 |
Alpha | -51.28 |
Beta | -6.17 |
Volatility | 215.68% |
Current Volume | 2.6k |
Average Volume 20d | 9.1k |
As of March 14, 2025, the stock is trading at USD 1.25 with a total of 2,606 shares traded.
Over the past week, the price has changed by -27.75%, over one month by +22.55%, over three months by +76.80% and over the past year by -79.97%.
Neither. Based on ValueRay Fundamental Analyses, ATI Physical Therapy is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 10.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ATIP as of March 2025 is 0.59. This means that ATIP is currently overvalued and has a potential downside of -52.8%.
ATI Physical Therapy has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold ATIP.
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ATIP ATI Physical Therapy will be worth about 0.6 in March 2026. The stock is currently trading at 1.25. This means that the stock has a potential downside of -49.6%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3 | 140% |
Analysts Target Price | 3 | 140% |
ValueRay Target Price | 0.6 | -49.6% |